Cognition Therapeutics公司宣布，将在其针对路易体痴呆相关精神症状的关键性临床试验中，将神经精神量表确立为主要疗效评估终点。这一决定标志着该公司在推进其核心疗法方面迈出了重要一步，旨在更精准地衡量药物对患者神经精神症状的改善效果。采用该量表作为主要终点，有助于更全面地评估治疗干预对患者行为和心理症状的影响，从而为后续的监管审批和临床实践提供关键数据支持。
Cognition Therapeutics公司宣布，将在其针对路易体痴呆相关精神症状的关键性临床试验中，将神经精神量表确立为主要疗效评估终点。这一决定标志着该公司在推进其核心疗法方面迈出了重要一步，旨在更精准地衡量药物对患者神经精神症状的改善效果。采用该量表作为主要终点，有助于更全面地评估治疗干预对患者行为和心理症状的影响，从而为后续的监管审批和临床实践提供关键数据支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.